Results 131 to 140 of about 12,232 (185)

When PCSK9 Inhibitors Don't Save the Day. [PDF]

JACC Case Rep
Soffer DE.
europepmc   +1 more source

PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes. [PDF]

Front Med (Lausanne)
Zhou Q, Liu X, Tang Y, Pan C, Bi X.
europepmc   +1 more source

Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease. [PDF]

BMC Nephrol
Tang H, Li X, Wang F, Liu H, Zhang X, Liu B, Wang B.   +6 more
europepmc   +1 more source

Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes - exploratory analysis of the EMSIACS trial. [PDF]

Sci Rep
Jing A, Wang J, Zhang M, Liang Y, Liu J, Zhang N, Wang J, Li X, Li C, Cui Z, Liu Y, Gao J.   +11 more
europepmc   +1 more source

Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis. [PDF]

Am J Cardiovasc Drugs
Raone L, Gritti V, Mandurino-Mirizzi A, Sparasci FM, Scotti V, Currao A, Colonna G, Ferlini M, De Luca L.   +8 more
europepmc   +1 more source

Sustaining the Promise of PCSK9 Inhibitors: Lessons from Real-World Adherence in China. [PDF]

J Atheroscler Thromb
Nohara A.
europepmc   +1 more source

PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial. [PDF]

BMJ Open
Chen Z, Ma S, Zhang J, Zhang R, Zhou M, Li C, Chen Y, Wang H, He Y, REPRESS trial investigator.   +9 more
europepmc   +1 more source

Effectiveness of PCSK9 inhibitors versus statins in type 2 diabetes and dyslipidemia: a propensity-matched study. [PDF]

Front Endocrinol (Lausanne)
Wu JY, Lin YM, Hsu WH, Liu T, Tsai YW, Huang PY, Chuang MH, Yu T, Lai CC.   +8 more
europepmc   +1 more source

Limitations of cholesterol lowering with PCSK9 inhibitors

The Lancet Diabetes & Endocrinology, 2017
openaire   +3 more sources

Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects. [PDF]

J Transl Med
Bosco G, Di Giacomo Barbagallo F, Di Marco M, Scilletta S, Miano N, Pistritto C, Tiralongo M, Di Stefano C, Pennisi G, De Francesco EM, Malaguarnera R, Di Pino A, Piro S, Scicali R.   +13 more
europepmc   +1 more source